Filing Flows

Filing Flows › Mirum Pharmaceuticals (MIRM) › Next earnings date

Mirum Pharmaceuticals (MIRM) earnings: missed the estimate

Mirum Pharmaceuticals (MIRM) reported on Nov 3, 2026 and missed the EPS estimate: −$0.42 against −$0.41 (-0.3%). Revenue was $186M for Q3 2026, +40% year over year. It beat the EPS estimate in 20% of the quarters on record.

Last result−0.3% vs estimate
Beat rate20%

The last report

Mirum Pharmaceuticals reported revenue of $186M for the third quarter 2026 (+40% Y/Y), net loss $40.8M: Livmarli $133M, Bile Acid Medicines $52.3M. How it makes money → · Every quarter →

Mirum Pharmaceuticals: EPS against the estimate, last 5 reportsMirum Pharmaceuticals: EPS against the estimate, last 5 reportsEstimateReported−$0.16$0.05Nov 25$0.06−$0.12Feb 26−$0.35−$1.08May 26−$0.75−$0.80Aug 26−$0.41−$0.42Nov 26
Latest (Nov 26): Estimate −$0.41, Reported −$0.42.

Mirum Pharmaceuticals' latest quarter

Mirum Pharmaceuticals, Q3 2026: revenue $186M (+40% year over year), operating margin -32.2%, net loss $40.8M, operating cash flow −$4.3M. The chart follows the revenue to costs, profit and cash.

Questions

Did Mirum Pharmaceuticals beat earnings?

Mirum Pharmaceuticals (MIRM) reported on Nov 3, 2026 and missed the EPS estimate: −$0.42 against −$0.41 (-0.3%).

When does MIRM report earnings?

The next date is not set yet.

Does Mirum Pharmaceuticals usually beat earnings?

It beat the consensus EPS estimate in 20% of the quarters on record.

Open the interactive view →

Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.